Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving Chemoimmunotherapy
P. Connor Johnson(Harvard University), Areej El‐Jawahri(Massachusetts General Hospital), Oreofe O. Odejide(Dana-Farber Cancer Institute), Jeffrey A. Barnes(Harvard University), Ephraim P. Hochberg(Massachusetts General Hospital), Caron A. Jacobson(Dana-Farber Cancer Institute), Philippe Armand(Harvard University), Reid W. Merryman(Harvard University), Ann S. LaCasce(Otsuka (Japan)), Jennifer L. Crombie(Dana-Farber Cancer Institute), Jacob D. Soumerai(Harvard University), Bridget Coffey(Brown University), David C. Fisher(Dana-Farber Cancer Institute), Daniel Yang(Massachusetts General Hospital), Robb S. Friedman(Harvard University), Jeremy S. Abramson(Massachusetts General Hospital), Joel Schwartz(Harvard University), Ronald W. Takvorian(Massachusetts General Hospital)
Cited by 4
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
|The Lancet Oncology|2010|852
Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial
|Journal of Clinical Oncology|2017|834
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595